Bavachinin protects the liver in NAFLD by promoting regeneration via targeting PCNA
Introduction: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease all over the world, and no drug is approved for the treatment of NAFLD. Bavachinin (BVC) is proven to possess liver-protecting effect against NAFLD, but its mechanism is still blurry. Objectives: With the use of...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-01-01
|
Series: | Journal of Advanced Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2090123223000590 |